SCHEMBL29619014

SCHEMBL29619014

Cc1noc(C)c1-c1cc(NC(=O)C2CC2)ccc1OC[C@H]1CCCCN1C(=O)OC(C)(C)C

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.42
RAB9A P51151 1/20 0.42
FPR3 P25089 1/20 0.40
FPR2 P25090 1/20 0.40
MAPT P10636 2/20 0.40
LMNA P02545 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
F2RL3 Q96RI0 4/20 0.39
ABL1 P00519 3/20 0.39
RIN1 Q13671 1/20 0.39
PTPN2 P17706 1/20 0.38
PTPN1 P18031 1/20 0.38
PTPN6 P29350 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
ALOX5AP P20292 1/20 0.37
FEN1 P39748 1/20 0.37
HTT P42858 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29619027 0.94 NPC1 (0.42) NPC1RAB9AMAPTLMNASMN1; SMN2
SCHEMBL29619035 0.91 F2RL3 (0.40) NPC1FPR3FPR2F2RL3ALOX5AP
SCHEMBL29619065 0.91 F2RL3 (0.38) NPC1FPR3FPR2F2RL3MEN1
SCHEMBL31663765 0.90 NPC1 (0.44) NPC1RAB9AFPR3FPR2LMNA
SCHEMBL31663763 0.90 NPC1 (0.44) NPC1RAB9AFPR3FPR2LMNA
SCHEMBL31663788 0.90 NPC1 (0.44) NPC1RAB9AFPR3FPR2LMNA
SCHEMBL31663807 0.87 NPC1 (0.44) NPC1RAB9AFPR3FPR2LMNA
SCHEMBL29619089 0.87 MCHR1 (0.37) NPC1FPR3FPR2MAPTF2RL3
SCHEMBL29619024 0.86 ALOX5AP (0.43) MAPTF2RL3ALOX5APFEN1
SCHEMBL29619033 0.85 F2RL3 (0.38) RAB9AMAPTLMNAF2RL3ALOX5AP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240376090-A1 ISOXAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERED RELATED THERETO ARENA PHARMACEUTICALS, INC. (US) 2024-11-14 US disclosed
EP-4236942-A1 ISOXAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO Arena Pharmaceuticals, Inc. (US) 2023-09-06 EP disclosed
WO-2022093850-A1 ISOXAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO ARENA PHARMACEUTICALS, INC. (US) 2022-05-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240376090-A1 ISOXAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERED RELATED THERETO HTR2A, HTR5A, HTR1A NPC1 2454/4885RAB9A 1623/4885FPR3 1746/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.